News

Article

Vectura to Incorporate HPAPI Capabilities into UK Facility

The company will expand the site to include six new containment isolators and a product development manufacturing laboratory.

Vectura, an inhalation contract development manufacturing organization, announced on Dec. 12, 2020 that it is expanding its capabilities at its Chippenham, UK, facility to handle and develop highly potent active pharmaceutical ingredients (HPAPIs).

The expansion will include the installation of six containment isolators and the inclusion of a product development manufacturing laboratory that will house development manufacturing equipment for dispensing, blending, co-milling, jet-milling, spray-drying, and blister-filling, the company said in a press release. The new project will also increase the containment capabilities at the site, allowing Vectura scientists to handle APIs with an occupational exposure limit as low as 0.1 µg/m3.

“As a leading inhalation development company, we are committed to developing capabilities to meet our customers’ needs,” said Geraldine Venthoye, Vectura’s chief scientific officer and executive vice-president of Product Development, in the company press release. “Many inhaled drugs targeting, for example, asthma and COPD [chronic obstructive pulmonary disease], rely on high potency because of the small doses delivered, so this investment is crucial to ensure we have the physical capabilities to go alongside our scientists’ expertise to develop medicines and treatments in the future.”

Source: Vectura

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content